シンポジウム14：認知症先制医療のフロントライン：その現状と課題
先制医療のための疾患バイオマーカー
2023 年 40 巻 4 号 p. 508-510
詳細
2023 年 40 巻 4 号 p. 508-510
Biomarkers for detecting Alzheimer disease (AD) are expected to play many roles in preemptive medicine. In addition to molecular imaging such as amyloid PET and tau PET, cerebrospinal fluid (CSF) Aβ42, phosphorylated tau and total tau have been used as biomarkers that reflect the pathological characteristics of AD, namely Aβ accumulation (A), tau accumulation (T), and neurodegeneration (N). In recent years, plasma biomarkers such as plasma Aβ and p–tau have also been developed. In this article, body fluid biomarkers for preemptive medicine of AD are reviewed.
